人物經(jīng)歷
教育經(jīng)歷
1990年畢業(yè)于白求恩醫(yī)科大學(xué),獲得醫(yī)學(xué)學(xué)士學(xué)位;
1997年畢業(yè)于同濟(jì)醫(yī)科大學(xué),獲得醫(yī)學(xué)碩士學(xué)位;
2000年畢業(yè)于華中科技大學(xué)同濟(jì)醫(yī)學(xué)院,獲得醫(yī)學(xué)博士學(xué)位。
工作經(jīng)歷
1990-1994年同濟(jì)醫(yī)科大學(xué)助教;
2000-2005年在美國(guó)佛羅里達(dá)大學(xué)醫(yī)學(xué)院病理學(xué)、免疫學(xué)和實(shí)驗(yàn)醫(yī)學(xué)系從事博士后研究工作;
2005-2009年任美國(guó)佛羅里達(dá)大學(xué)醫(yī)學(xué)院病理學(xué)、免疫學(xué)和實(shí)驗(yàn)醫(yī)學(xué)系的Assistant Scientist;
自2008年起任湖南大學(xué)生物學(xué)院教授;
2010年起兼任湖南省腫瘤醫(yī)院(中南大學(xué)湘雅醫(yī)學(xué)院附屬腫瘤醫(yī)院)教授。
教授課程
主講生物學(xué)院本科生《藥理學(xué)》課程。
主講生物學(xué)院研究生《專業(yè)英語(yǔ)》課程。
研究方向
主要從事分子病毒學(xué)與免疫學(xué)、腫瘤分子生物學(xué)領(lǐng)域的教學(xué)和科研工作。具體研究?jī)?nèi)容包括病毒與宿主的相互作用、腫瘤細(xì)胞信號(hào)傳導(dǎo)及耐藥機(jī)制、病毒及腫瘤細(xì)胞的免疫逃逸機(jī)制,以及消化道腫瘤和肝炎新型靶向藥物、疫苗的研發(fā)。
科研成果
研究成果
多年來一直從事消化道腫瘤和肝炎的發(fā)病機(jī)制、耐藥機(jī)制以及藥物與疫苗研發(fā)工作。主持承擔(dān)國(guó)家科技重大專項(xiàng)、國(guó)家自然科學(xué)基金等多項(xiàng)科研項(xiàng)目,共計(jì)科研經(jīng)費(fèi)1000余萬元。在PNAS、Gastroenterology、Hepatology、J Virology等國(guó)際頂級(jí)學(xué)術(shù)刊物上發(fā)表70余篇論文,其中多篇論文被撰寫述評(píng)和作為研究亮點(diǎn)報(bào)道。多次應(yīng)邀在病毒性肝炎和肝病國(guó)際國(guó)內(nèi)學(xué)術(shù)會(huì)議上作特邀報(bào)告。獲得1項(xiàng)美國(guó)發(fā)明專利并授權(quán),申請(qǐng)了另一項(xiàng)美國(guó)和歐盟發(fā)明專利,申請(qǐng)了多項(xiàng)國(guó)家發(fā)明專利,其中5項(xiàng)已獲授權(quán)。獲得湖南省科技進(jìn)步獎(jiǎng)1項(xiàng)。
科研項(xiàng)目
1、“核酸適體在丙型病毒性肝炎早期診斷和靶向治療中的應(yīng)用基礎(chǔ)研究”(2009ZX10004-312) “艾滋病和病毒性肝炎等重大傳染病防治”國(guó)家科技重大專項(xiàng)768萬元。
2、“丙型病毒性肝炎發(fā)病機(jī)制探討” 教育部新世紀(jì)優(yōu)秀人才支持計(jì)劃 50萬元。
3、“肝炎病毒感染小鼠模型的構(gòu)建” 湖南省科研條件創(chuàng)新專項(xiàng) 5萬元。
學(xué)術(shù)成果
代表論文
1. Eksioglu E, Bess J,Zhu H, Xu Y, Dong H, Elyar J, Nelson DR, Liu C. Hepatitis C virus modulates human monocyte-derived dendritic cells.J Vir Hepat2010; 17:757-769 (IF:3.348)。
2. Eksioglu EA, Bess J, Jones G, Dettloff J, Dangmeon P, Dong HJ,Zhu H, Firpi R, Xu Y, Nelson DR, Liu C. Characterization of anti-HCV antibodies in IL-10 treated patients.Viral Immunology2010;23:359-368 (IF:1.779)。
3.Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Primary human hepatocyte culture for HCV study.Methods Mol Biol, 2009 510:373-382。
4. Kenworthy R, Lambert D, Yang F, Wang N, Chen Z,Zhu H, Zhu F, Liu C, Li K, Tang H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation.Nucleic Acids Res.2009;37:6587-6599 (IF: 7.48)。
5. Wu H,Zhu H, Zhuang J, Liu C, Cao YC. Water-soluble nanocrystals through dual-interaction ligands.Angew Chem Int Edit.2008; 47:3730-34. (IF: 11.829)Butler SL, Dong H, Cardona D, Jia M, Zheng R,Zhu H, Crawford JM, Liu C. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1.Lab Invest2008; 88:78-88. (IF: 4.602)。
6.Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford CM, Nelson DR, Liu C. Hepatitis C virus triggers cell death through innate intracellular antiviral defense system.Gastroenterology2007; 133:1649-1659 (IF: 12.899)。
7. Liu C,Zhu H, Subramanian MG, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture.Hepatology Research. 2007; 37:941-947. (IF: 1.540)。
8. Cao M, Cabrera R, Xu Y, Firpi R,Zhu H, Liu C, Nelson DR. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.Lab Invest. 2007, 87:582-590. (IF: 4.602)。
9.*Firpi RJ,Zhu H, Morelli G, Abdelmalek MF, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increase the chance of sustained virological response after liver transplantation.Liver Transplantation2006, 12:51-57(see Editorial on Page 19-21)(IF: 4.085)。
10.Zhu H, Butera M, Nelson DR and Liu C. Novel type I Interferon IL-28A suppresses hepatitis C viral RNA replication.Virology J2005, 2:80 (IF: 2.435)。
11.Zhu H, Nelson DR, Crawford JM and Liu C. Defective JAK-STAT activation in host cells confers hepatitis C viral interferon-alpha resistance.J of Interferon and Cytokine Res2005, 25(9): 528-539 (IF: 1.627)。
12. Rufforny I, Wilkinson EJ, Liu C,Zhu H, Buteral M, Massoll NA. Human papillomavirus infection and p16 (INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma.J Lower Genital Tract Disease. 2005, 9(2):108-113。
13.Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells.Biochem and Biophys Res Commun2004; 324:518-528 (IF: 2.55)。
14. Shang XZ,Zhu H, Lin K, Tu Z, Chen J, Nelson DR and Liu C. Stabilized b-catenin promotes hepatocyte proliferation and inhibits TNFa-induced apoptosis.Laboratory Investigation2004; 84:332-341 (IF: 4.602)。
15. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M,Zhu H, Xu YL, Cabrera R, Liu C and Davis G. Long-term interleukin10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.Hepatology2003; 38:859-868 (IF: 11.355)。
16. *Liu C,Zhu H, Tu Z, Xu YL and Nelson DR. CD8+ T cell interaction with HCV replicon cells: evidence for both cytokine- and cell—mediated antiviral activity.Hepatology2003; 37:1335-1342 (IF:11.355)
17.*Zhu H, Zhao H, Collins CD, Eckerrode SE, Ruan Q, Mcindoe RA, Crawford JM, Nelson DR, She JX and Liu C. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.Hepatology2003; 37:1180-1188(see Editorial on Page 975-978)(IF: 11.355)。
18.Zhu Hand Liu C. Interleukin-1 inhibit hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway.J Virology2003; 77:5493-5498 (IF: 5.15)。
19.Zhu HZ, Ruan YB, Wu ZB and Zhang CM. Kupffer cell and apoptosis in experimental HCC.World J Gastroenterol2000; 6:405-407(IF:2.092)。
20.Zhu H, Ruan Y, Yang M, Wu Z, Zhang C. The influence of Kupffer cells on apoptosis in the experimental hepatocellular carcinoma.Chinese Journal of Histochemistry and Cytochemistry2000; 9:138-141。
21. Staudacher C, Chiappa A, Zbar AP, Bertani E, Biella F,Haizhen Z. Evalution of risk factors in the development of postoperative complications in patients undergoing liver resection for cancer.Chir Itl2000; 52:123-129。
22.Zhu H, Ruan Y, Wu Z. The influence of Kupffer cells on the expression of apoptosis related genes in experimental hepatocellular carcinoma.Acta Univ Med Tongji2000; 29:97-99。
23.Zhu H, Ruan Y, Yang M, Wu Z and Ivankovic S. The role of Kupffer cells in experimental hepatocarcinogenesis: a microscopic, light and electron microscopic observation.Acta Univ Med Tongji1998; 27:420-422, 430。
24.Zhu H, Ruan Y, Wu Z. The influence of Kupffer cells on experimental hepatocarcinogenesis.Zhonghua Bing Li Xue Za Zhi [Chin J Pathol]1998; 27: 102-104。
學(xué)術(shù)專著
1.Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Chapter 28 Primary human hepatocyte culture for HCV study.Hepatitis C: Methods and Protocols (2Edition).Vol 510Methods Mol Biol, p373-382. The Humana Press, 2009。
專利發(fā)表
Human liver cancer cell line. International Application No. PCT/US2007/ 006722.